Ompranyt (Omeprazole)

Omeprazole, the active ingredient in Ompranyt, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and adolescents. GNH USA supplies Ompranyt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ompranyt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ompranyt is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates when used with antibiotics. - NSA‑ID‑induced gastropathy: lowers the risk of ulcer formation in patients requiring long‑term NSAID therapy.

Adverse reactions to Ompranyt are generally mild to moderate and vary with duration of therapy.

Common Side Effects: - Headache: mild, transient headache reported in clinical studies. - Diarrhoea: loose stools occurring especially during the first weeks of treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort or cramping. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements in some patients.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis reported with prolonged use. - Hypomagnesemia: low serum magnesium levels with long‑term therapy. - Acute interstitial nephritis: kidney inflammation observed rarely. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use. - Vitamin B12 deficiency: reduced absorption with chronic therapy.

Ompranyt should be used with consideration of patient‑specific factors and proper storage.

- Assess renal function: dose adjustment may be required in severe renal impairment. - Evaluate hepatic function: use with caution in moderate to severe liver disease. - Review concomitant medications: potential for drug‑drug interactions, especially with antiplatelet agents. - Monitor long‑term users: watch for magnesium deficiency, bone health and vitamin B12 status. - Pregnancy and lactation: prescribe only if the benefit outweighs potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Ompranyt can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Digoxin: higher serum levels may occur, check renal function and drug levels. - Methotrexate: reduced clearance, monitor for toxicity. - Phenytoin: decreased plasma concentration, observe seizure control. - Iron supplements: lower absorption, separate dosing times by at least 2 hours.